
Invetx Completes Development of Canine and Feline Half-Life Extension Technology Platform that Significantly Extends Duration of Monoclonal Antibody Treatment Effect
Boston, MA- July 25, 2023 – Invetx, a pioneer in protein-based therapeutics for animal health, announced that it has recently completed development of its species-specific, half-life extension technology for dogs and cats which leads to superior extended duration of activity for the company’s veterinary monoclonal antibodies.
Invetx Appoints Dr. Marcus Remmers, Novo Holdings Partner and Animal Health Industry Leader, to Board of Directors
Boston, MA – June 26, 2023- Invetx, a pioneer in protein-based therapeutics for animal health, today announced the appointment of Dr. Marcus Remmers to its board of directors.
Invetx Announces Oversubscribed Series B Financing of $60.5 Million to Advance Portfolio of Best-in-Class Veterinary Biotherapeutics
Company positioned to bring portfolio of novel antibody product candidates through development to market approval Round includes new investors F-Prime Capital, Novo Holdings, GV and
Twist Bioscience Expands Partnership with Invetx to Include Discovery of Best-in-Class Antibodies to Treat Multiple Diseases in Cats and Dogs
SOUTH SAN FRANCISCO and BOSTON, Mass. – November 18, 2021 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering
Boehringer Ingelheim and Invetx Announce Strategic Collaboration to Advance Monoclonal Antibody Biotherapeutics in Animal Health
Collaboration Focused on Discovery, Development and Commercialization of Novel Veterinary Medicines Ingelheim, Germany and Boston, MA- September 27, 2021- Boehringer Ingelheim, a global leader in
Invetx Announces Initiation of First Clinical Study in Dogs with IVX-01, its Novel Monoclonal Antibody Featuring Half-Life Extension
Company Appoints Dr. Robert Zolynas as Vice President, Clinical Development & Regulatory Affairs Boston, MA- September 20, 2021- Invetx, a pioneer in protein-based therapeutics for
Invetx Announces Completion of $25.5 Million Series A Financing and Key Appointments to Executive Team
New Investors Include Casdin Capital and Tekla Capital Antibody Development Experts Bill Brondyk, PhD, Named Chief Scientific Officer and Colin Giles, PhD, Chief Development
Invetx Announces Industry-Leading Antibody Discovery Platform to Develop Portfolio of Novel Therapeutics for Animal Health
Platform Leverages Best-in-Class Technologies from AbCellera, Twist Bioscience and WuXi Biologics BOSTON, Mass. – July 16, 2020 – Invetx, a pioneer in protein-based therapeutics for
Twist Bioscience Partners with Invetx to Deliver Best-in-Class Antibody Therapeutics for Dogs and Cats
SOUTH SAN FRANCISCO and BOSTON, Mass. – July 16, 2020 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering
